Therapy Efficacy Method via Tissue Analysis, Arion Diagnostics
Summary
USPTO granted Patent US12599349B2 to Arion Diagnostics, Inc. covering a method for determining therapeutic agent efficacy through non-invasive biological tissue characterization. The method involves measuring molecular structure of tissue at two time points and observing changes to determine efficacy. The patent includes 27 claims and covers therapeutic applications across multiple CPC classifications including oncology, immunology, and neurological disorders.
What changed
USPTO granted Patent US12599349B2 to Arion Diagnostics, Inc. for a method of determining therapeutic agent efficacy using non-invasive tissue analysis. The method involves measuring molecular structure of biological tissue at first and second time points and observing changes to assess whether a therapeutic agent is effective. Inventors are Alexander P. Lazarev, Delvin Tai Wai Yuk, and Pavel Lazarev.
For competitors and researchers in therapeutic development and diagnostics, this patent grants Arion Diagnostics exclusive rights to tissue-based efficacy determination methods, potentially restricting development of similar non-invasive therapy monitoring techniques without license.
What to do next
- Monitor for updates
Archived snapshot
Apr 15, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Determining a therapy efficacy
Grant US12599349B2 Kind: B2 Apr 14, 2026
Assignee
Arion Diagnostics, Inc.
Inventors
Alexander P. Lazarev, Delvin Tai Wai Yuk, Pavel Lazarev
Abstract
The present disclosure relates to determining an efficacy of a therapeutic agent. A method for determining an efficacy of a therapeutic agent for a target disease can include measuring a molecular structure of a biological tissue of an animal at a first time and at a second time using a non-invasive biological tissue characterization technique. The method can further include observing a change of the molecular structure of the biological tissue between the first time and the second time, and determining the efficacy of the therapeutic agent based on the observed change in the molecular structure of the biological tissue. Before the first time, or between the first time and the second time, the animal received the therapeutic agent.
CPC Classifications
A61P 35/00 A61P 37/04 A61P 11/00 A61P 25/00 A61P 1/04 A61P 43/00 A61P 29/00 A61P 19/02 A61P 17/02 A61P 13/02 A61P 13/08 A61P 13/10 A61P 13/12 A61P 15/00 A61P 17/00 A61P 27/02 A61P 3/00 A61P 3/06 A61P 3/08 A61P 3/10 A61P 31/00 A61P 31/04 A61P 31/12 A61P 31/18 A61P 35/02 A61P 37/02 A61P 37/06 A61P 7/00 A61P 7/04 A61P 9/00 A61P 25/02 A61P 25/04 A61P 25/16 A61P 25/28 A61P 35/04 A61N 1/37 A61N 5/10 A61N 1/3629 A61B 5/0071 A61B 5/0075 A61B 5/4839 A61B 6/502 A61B 5/4848 A61B 5/7257 A61B 5/7275 A61B 5/7282
Filing Date
2023-04-10
Application No.
18298218
Claims
27
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.